Recombinant human preproinsulin expression, purification and reaction with insulin autoantibodies in sera from patients with insulin-dependent diabetes mellitus by Berg, Heike et al.
Journal of Immunological Methods, 164 (1993) 221-231 221 
© 1993 Elsevier Science Publishers B.V. All rights reserved 0022-1759/93/$06.00 
JIM 06789 
Recombinant  human preproinsulin 
Expression, purification and reaction with insulin autoantibodies in sera 
from patients with insulin-dependent diabetes mellitus 
Heike Berg a, Michael  Wal ter  u, Ludwig Mauch a, Jochen Seissler c 
and Wolfgang Nor themann a
a Department of Molecular Biology, ELIAS Entwicklungslabor, D-79114 Freiburg, Germany, 
b Institute of Genetics, University of Diisseldorf, D-40225 Diisseldorf,, Germany, and 
c Department of Internal Medicine I, University of Ulm, D-89081 Ulm, Germany 
(Received 9 December 1992, revised received 19 March 1993, accepted 10 May 1993) 
A novel prokaryotic expression vector pGEX-6T was designed for high-level expression of recombi- 
nant fusion protein with a histidine-hexapeptide and glutathione-S-transferase at its N-terminus and the 
recombinant human preproinsulin at its C-terminus. Efficiency of expression was investigated in the 
Escherichia coli strain CAG456. The synthesized protein was sequestered in an insoluble form in 
inclusion bodies and was purified to homogeneity by one-step affinity chromatography based on the 
specific complex formation of the histidine-hexapeptide and a chelating matrix which was charged with 
Ni 2+ ions. The antigenic nature of the purified recombinant preproinsulin fusion protein was evaluated 
by ELISA screening for insulin autoantibodies in selected sera from patients with recent-onset type 1 
(insulin-dependent) diabetes mellitus classified by the existence of additional autoantibodies reactive 
against glutamic acid decarboxylase. 14% of the tested sera (n = 43) contained insulin autoantibodies 
which strongly recognized the recombinant human preproinsulin. Comparable measurements with both 
recombinant human preproinsulin and mature insulin suggested that the observed autoantigenicity of 
preproinsulin was mediated by the C-peptide or /and  signal peptide. 
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Introduction 
Many eukaryotic proteins that are of interest 
for basic research or for medical applications 
such as diagnostic assays are often not available 
in the desired amount and purity from natural 
sources. Therefore, cloning and expression of for- 
eign genes in various biological systems such as 
bacterial, yeast and mammalian cells are common 
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procedures providing a ready source of these 
proteins. In the present paper we describe cDNA 
cloning and expression of recombinant human 
preproinsulin i  Escherichia coli with respect o 
two objectives. First, we established satisfactory 
synthesis and purification of recombinant human 
preproinsulin as a fusion protein using the novel 
prokaryotic expression system pGEX-6T followed 
by a specific single-step urification based on 
affinity chromatography with a metal chelating 
matrix (Berthold et al., 1992). Second, we wished 
to evaluate recombinant human preproinsulin as 
a possible antigenic tool in ELISA measurements 
of insulin autoantibodies (IAA), e.g., in selected 
sera from patients with insulin-dependent dia- 
betes mellitus (IDDM) which also contained au- 
toantibodies directed against the 65 kDa glutamic 
acid decarboxylase (GAD65). 
Type 1 (insulin-dependent) diabetes mellitus is 
one of most severe and common autoimmune 
diseases characterized by irreversible and selec- 
tive destruction of insulin-producing /3 cells in 
the pancreas and circulating islet specific autoan- 
tibodies which are present for years before clini- 
cal onset of the disease (for review see Castano 
and Eisenbarth, 1990; Boitard and Bach, 1991; 
Harrison, 1992). The detection of these autoanti- 
bodies in non-diabetic individuals indicates risk 
for IDDM and prediabetic insulitis. The anti- 
GAD65 autoantibodies are one of the earliest 
detectable islet-cell autoantibodies (Baekkeskov 
et al., 1982, 1990). While the anti-GAD65 autoan- 
tibody is currently the best studied of the islet- 
specific autoantibodies and serves as the most 
relevant serological marker for ongoing /3 cell 
destruction, the generation of insulin autoanti- 
bodies (IAA) alone confers relatively little risk 
for IDDM development. 
Material and methods 
Isolation of human preproinsulin cDNA 
Approximately 1.5 x 106 clones of a human 
pancreatic arcinoma cDNA library in A-gtll 
(Clontech) were screened with a synthetic 
oligonucleotide corresponding to the cDNA se- 
quence of human insulin (Goedel et al., 1980). 14 
positive clones were obtained. Corresponding cD- 
NAs were isolated from the A clones, subcloned 
into plasmid Bluescript SK(f-) (Stratagene) and 
characterized by sequence analysis. The clone 
pPPI.3 carried the longest insert with 541 bp in 
length coding for the entire human preproinsulin 
including extended non-coding 5' and 3' regions 
and with a polyA stretch of 65 adenosines. 
Expression of the preproinsulin fusion protein in 
Escherichia coli 
Various E. coli strains transformed with the 
plasmid pPPI.304 were cultured overnight in LB 
medium containing 150/zg/ml ampicillin, diluted 
ten-fold with fresh prewarmed LB medium and 
incubated for 60 min prior to induction with 1 
mM IPTG for 5 h. Bacteria in aliquots of 100/zl 
culture medium were sedimented, resuspended in 
sample buffer and applied to 10% polyacryl- 
amide-SDS gel electrophoresis. 
Immunoblotting 
The proteins were separated by 10% polyacryl- 
amide-SDS gel electrophoresis under reducing 
conditions and transferred to nitrocellulose filters 
(Amersham) using a trans-blot semi-dry elec- 
trophoretic transfer c ll (Bio-Rad). The unoccu- 
pied protein-binding sites on the filter were 
blocked with 5% non-fat dried milk in TBST 
buffer (10 mM Tris/HC1, pH 8.0, 150 mM NaCI, 
0.05% Tween 20). The immobilized proteins were 
incubated for 2 h with a 500-fold dilution of 
anti-porcine insulin serum from guinea pig 
(Sigma) or sera from IDDM patients. The anti- 
porcine insulin serum was preabsorbed with 0.1 
mg/ml crude extract derived from E. coli strain 
LE392 transformed with pGEX-6T. The bound 
antibodies were visualized either with anti-guinea 
pig immunoglobulins (Sigma) or anti-human im- 
munoglobulins (Promega) conjugated with alka- 
line phosphatase, respectively. 
Purification of the recombinant preproinsulin fu- 
sion protein 
E. coli strain CAG456 (Snyder et al., 1987) 
transformed with pPPI.304 was cultured in 100 
ml LB medium and induced with 1 mM IPTG for 
5 h. The cells were sedimented, resuspended in 
20 ml PBS and treated with 1.0 mg/ml lysozyme 
(Sigma) and 1 mM phenylmethylsulfonyl fluoride 
(Sigma) for 20 min at 0°C followed by incubation 
with 1% Triton X-100 (Sigma) for 10 min at 0°C. 
The cells were lysed by sonication with two pulses 
for 20 s each at about 100 W at 0°C. The soluble 
and insoluble cell fractions were separated by 
centrifugation f the cell homogenate at8000 × g 
and 4°C for 5 rain. The pellet containing the 
insoluble recombinant preproinsulin fusion pro- 
tein was dissolved in 50 ml 6 M guanidinium-hy- 
drochloride in Tris/acetate buffer (50 mM 
Tris/acetate, pH 7.8, 0.5 M NaCI) and directly 
applied onto a 10 ml chelating Sepharose FF 
column (Pharmacia) which was charged with 
nickel ions according to the producer's tandard 
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protocol (Pharmacia). The column was developed 
with a pH step gradient of pH 6.0, pH 5.5., pH 
5.0 and pH 4.0 as described previously (Berthold 
et al., 1992). The recombinant protein eluted at
pH 4.0 was dialysed against 6 M guanidinium-hy- 
drochloride in Tris/acetate buffer, pH 7.8, with- 
out NaCI and treated with 20 mg/ml sodium 
sulfite, 10 mg/ml sodium tetrathionate and 1 mM 
EDTA for oxidative sulfitolysis for 6 h at room 
temperature (Patrick and Lagu, 1992). After sub- 
sequent dialysis against 2 M urea in 20 mM 
Tris/acetate, pH 8.0, and PBS at room tempera- 
ture the preproinsulin fusion protein was concen- 
trated and stored at -20°C. The recombinant 
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GST was expressed by pGEX-6T and purified 
with the same protocol. 
ELISA screening for anti-insulin autoantibodies 
The antigens were diluted in phosphate- 
buffered saline (PBS) and applied to microtiter 
plates at concentrations of 1 ~zg/ml. The coating 
was performed with 120/zl/well for 16 h at 4°C. 
The plates were blocked with PBS containing 
0.5% bovine serum albumin (BSA), 1% lactose 
and 0.02% sodium azide, dried and stored in 
sealed bags until use at 4°C. The ELISA proce- 
dure was performed with 100/xl aliquots of serum 
from each patient which were diluted 100-fold 
with PBS supplemented with 0.5% BSA and 
0.05% Tween 20. Samples were incubated in the 
plate for 30 min at room temperature. To prevent 
nonspecific immunoreaction the diluted sera were 
pretreated with a 0.1 mg/ml extract from E. coli 
strain LE392 transformed with pGEX-6T. After 
washing the plates, bound antibodies were visual- 
ized with rabbit anti-human IgG conjugated with 
horseradish peroxidase for 15 min at room tem- 
perature followed by a color reaction with o- 
phenylenediamine. The extinction was measured 
bichromatically at 492 nm with a 640 nm refer- 
ence. The concentrations of IAA expressed in 
arbitrary units (U/ml) were calculated from a 
standard curve. The standard used in this im- 
munoassay was taken from a commercially avail- 
able insulin antibody ELISA kit (SYNELISA, 
ELIAS Medizintechnik) and comprised an iso- 
lated and defined immunoglobulin fraction 
specifically directed against highly purified hu- 
man mature insulin. The interassay variance was 
less than 10% at all analyte levels. All measure- 
ments were undertaken with an automatic ELISA 
reader (SLT Labinstruments) using commercially 
available SYNELISA software (ELIAS Medizin- 
technik). 
Autoantibodies 
All sera from autoimmune patients with re- 
cent-onset IDDM tested in this study were posi- 
tively assayed for anti-GAD65 autoantibodies by 
immunoprecipitation as described previously 
(Seissler et al., 1992). The antigen sample for 
screening the sera of patients was metabolically 
labeled recombinant full-length human GAD65 
which was expressed in infected Spodoptera 
frugiperda (Sf9) insect cells mediated by recombi- 
nant baculovirus Autographa californica (L. 
Mauch, unpublished results). 
Results 
Construction of vector pGEX-6T 
The initial expression vector pGEX-3T (Fro- 
rath et al., 1992) was modified in order to insert a 
I<-- GST 
MSPIHHHHHH LLGYWKIKGL VQPTRLLLEY LEEKYEEHLY ERDEGDKWRK 50 
KKFELGLEFP NLPYYIDGDV KLTQSMAIIR YIADKHNMLG GCPKERAEIS I00 
MLEGAVLDIR YGVSRIAYSK DFETLKVDFL SKLPEMLKMF EDRLCHKTYL 150 
NGDHVTHPDF MLYDALDWL YMDPMCLDAF PKLVCFKKRI EAIPQIDKYL 200 
GST -->I I<-- preproinsulin 
KSSKYIAWPL QGWQATFGGG DHPPKSVDDD DKGALWMRLL PLLALLALWG 250 
PDPAAAFVNQ HLCGSHLVEA LYLVCGERGF FYTPKTRREA EDLQVGQVEL 300 
-->I 
GGGPGAGSLQ PLALEGSLQK RGIVEQCCTS ICSLYQLENY CN 342 
Fig. 2. Amino acid sequence of the preproinsulin fusion protein. The amino acid sequence was deduced from the analysed cDNA 
sequence of the GST fusion gene coding for a fusion protein with the GST (aa no. 13-224) at its N-terminus and human 
preproinsulin (aa no. 234-342) at its C-terminus as indicated. Both the histidine-hexapeptide and the enterokinase recognition 
sequence are underlined. 
coding sequence for histidine-hexapeptide (HI_ 6) 
and to replace the thrombin cleavage site by a 
corresponding recognition sequence (VDDD-  
DKG)  for the site-specific enterokinase by corre- 
sponding oligonucleotide linker cloning (data not 
shown). The enterokinase cleavage site provided 
the option of cleaving the GST moiety of the 
purified fusion protein, if necessary (Hopp et al., 
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1988; Su et al., 1992). The new expression vector, 
pGEX-6T  (Fig. 1), is 5023 bp long and directs the 
expression of recombinant fusion protein with 
glutathione-S-transferase (GST) combined with a 
histidine-hexapeptide as an affinity tail at its N- 
terminus. The highly efficient synthesis of recom- 
binant protein is controlled by a tac -promoter  
(Amman et al., 1983) which is normally repressed 
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Fig. 3. Expression of recombinant preproinsulin fusion protein in various E. col  strains and their immunoblotting analysis. The E. 
coli strains CAG456 (lane 2), CAG440 (lane 3), GEl96 (lane 4), LE392 (lane 5) and XL1-Blue (lane 6) were transformed with 
pPPI.304. Aliquots of 100 ~1 of bacterial cultures induced with 1 mM IPTG for 5 h were sedimented, resuspended in sample buffer 
and analyzed by10% polyacrylamide-SDS gel electrophoresis. After eparation the proteins were stained with Coomassie brilliant 
blue (A) or analyzed by immunoblotting using anti-porcine insulin serum (B). A  a control, E. coli LE392 was transformed with 
pGEX-6T expressing the 26 kDa GST (lane 1). M = -Size markers. 
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by the lac repressor mediated by the lacI q gene 
located on the plasmid until induction with IPTG. 
Construction and expression of preproinsulin cDNA 
clone 
In order to express the recombinant human 
preproinsulin as a GST fusion protein the full- 
length cDNA with 541 bp was isolated from the 
clone pPPI.3 in Bluescript, trimmed to remove 
the 5' non-coding region including the initial 
codon for methionine by oligonucleotide linker 
replacement and inserted into the multicloning 
site of pGEX-6T resulting in the cDNA clone 
pPPI.304. The correct protein reading frame of 
the resulting GST fusion gene was established by 
DNA sequence analysis (Fig. 2). 
Five E. coli strains, CAG456, CAG440, GEl96, 
LE392, and XL1-Blue, were transformed with 
pPPI.304 and analysed for yield of the recombi- 
nant preproinsulin fusion protein. As a control 
the E. coil strain LE392 was transformed with 
pGEX-6T expressing the 26 kDa GST. After 
induction with 1 mM IPTG for 5 h, aliquots of 
the bacterial culture were analysed by polyacryl- 
amide-SDS gel electrophoresis prior to staining 
of the proteins (Fig. 3A). Correct expression of 
the preproinsulin fusion protein with the ex- 
pected molecular weight of 38 kDa was con- 
firmed by immuno blotting analysis using com- 
mercially available anti-porcine insulin (Fig. 3B). 
The highest yield of recombinant protein was 
obtained with E. coil strains CAG456 and 
CAG440 (Fig. 3, lanes 2 and 3). The synthesised 
recombinant protein was gradually accumulated 
in CAG456 cells over a time period of 24 h (Fig. 
4). Under optimal conditions the preproinsulin 
fusion protein accounted for up to 20% of total 
cellular proteins. 
Purification of the recombinant preproinsulin fu- 
sion protein by affinity chromatography 
The recombinant preproinsulin fusion protein 
was designed with an N-terminal histidine 
hexapeptide that permitted the simplified purifi- 
cation of recombinant proteins from bacterial 
lysates by affinity chromatography using a metal 
chelating matrix as previously described (Berthold 
et al., 1992). To examine whether the recombi- 
nant preproinsulin fusion protein directed by the 
kDa 
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Fig. 4. Expression kinetics of recombinant human preproin- 
sulin fusion protein. Cultures of E. coli CAG456 transformed 
with pPPI.304 were induced with 1 mM IPTG for 0 h (lane 1), 
1 h (lane 2), 2 h (lane 3), 4 h (lane 4), 6 h (lane 5), 8 h (lane 6), 
12 h (lane 7) and 24 h (lane 8). Bacterial proteins  100 ~1 
aliquots of culture fluid were separated by 10% poly- 
acrylamide-SDS gel electrophoresis and stained. (M)= Size 
markers. 
clone pPP.304 was synthesized as a soluble or 
insoluble protein, the transformed E. coli strain 
CAG456 was induced with IPTG and lysed by 
sonication. The cell homogenate was separated 
into soluble and insoluble cell fractions by cen- 
trifugation and analysed by gel electrophoresis 
(Fig. 5, lanes 1, 2 and 3). The synthesized pre- 
proinsulin fusion protein was mainly sequestered 
as an insoluble cell fraction in inclusion bodies 
(Fig. 5, lane 3). In order to purify the recombi- 
nant protein the inclusion bodies were solubilized 
in 6 M guanidinium-hydrochloride and applied to 
a chelating Sepharose column charged with Ni 2+ 
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ions (Berthold et al., 1992). The recombinant 
protein was eluted gradually at pH 5.5 and 4.0 
(Fig. 5, lanes 5 and 6). The eluate at pH 4.0 
contained recombinant preproinsulin fusion pro- 
tein in almost pure form. Following dialysis the 
low solubility of the recombinant preproinsulin 
fusion protein could induce precipitation and in 
order to prevent this the intermolecular and in- 
tramolecular disulfide bridges were permanently 
disrupted by reaction with sulfite and tetrathion- 
ate a technique known as oxidative sulfitolysis 
(Patrick and Lagu, 1992). With this technique the 
purification of preproinsulin fusion protein 
yielded about 1.2 mg soluble recombinant protein 
kDa 
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- 43 .0  
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Fig. 5. Purification of recombinant human preproinsulin fu- 
sion protein. E coli strain CAG456 transformed with pPPI.304 
was cultured, induced with 1 mM IPTG for 5 h and fraction- 
ated to purify the recombinant fusion protein. 100/~l aliquots 
of culture fluid were removed from different cell fractions and 
from several steps of the purification by affinity chromatogra- 
phy on a metal chelating Sepharose FF column. E. coli lysate 
(lane 1), soluble cell fraction (lane 2), insoluble cell fraction 
(lane 3), fraction eluted at pH 5.5 (lane 4), at pH 5.0 (lane 5) 
and at pH 4.0 (lane 6). (M) = Size markers. 
per 100 ml bacterial culture of transformed E. 
coli. 
ELISA screening of IAA in sera of patients with 
IDDM using recombinant preproinsulin fusion pro- 
tein 
For the determination of IAA in sera from 
patients with IDDM a quantitative immunoassay 
(ELISA) was established with recombinant hu- 
man preproinsulin fusion protein as an immobi- 
lized antigen target. In total 43 sera derived from 
patients with recent-onset IDDM and 39 sera 
from blood donors were compared (Fig. 6). The 
sera of the patients were positively selected for 
anti-GAD autoantibodies as a specific serum 
marker for IDDM measured by immunoprecipi- 
tation of metabolically labeled recombinant hu- 
man GAD65 which was expressed by baculovirus 
in infected Sf9 cells (data not shown). With refer- 
ence to the standard a cut-off was set at 10 U /ml  
between positive and negative sera. Six sera from 
patients with IDDM (14.0%) and one serum 
among blood donors (2.6%) reacted significantly 
with the recombinant preproinsulin fusion pro- 
tein and exhibited IAA concentrations above the 
cut-off value (Fig. 6). The sera from the blood 
donors were randomly selected from a large pool. 
All sera used for the ELISA screening of IAA 
were pretreated with lysates of E. coli trans- 
formed with pGEX-6T which provided sufficient 
amounts of recombinant GST to prevent nonspe- 
cific reactions of the sera with the GST moiety of 
the preproinsulin fusion protein as well as with 
contaminating E. coli proteins (data not shown). 
No positive reactions were observed in ELISA 
measurements of the same pool of sera from 
IDDM patients based on recombinant mature 
human insulin as antigen target (data not shown). 
Immunoblotting analysis with either purified 
recombinant preproinsulin fusion protein or GST 
as control were performed in order to confirm 
the positive ELISA measurements of the six sera 
from IDDM patients (Figs. 7B-7G)  and the one 
ser m from blood donors (Fig. 7H). As shown in 
Fig. 7 only five of the positive IDDM sera (11.6%) 
and the positive serum from the blood donors 
(2.6%) maintained their strong reactivity with the 
recombinant preproinsulin fusion protein. These 
data clearly indicated the existence of linear anti- 
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Fig. 6. ELISA screening of insulin autoantibodies in sera from patients with IDDM and blood donors using the recombinant 
preproinsulin fusion protein. Concentration f IAA illustrated in arbitrary units (U/ml) were assayed in 43 sera from patients with 
IDDM (group 1) and in 39 sera from blood donors (group 2) by an ELISA procedure using the preproinsulin fusion protein. 
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Fig. 7. Immunoblotting analysis of recombinant preproinsulin fusion protein using IAA positive IDDM sera. 2 /zg of purified 
recombinant GST (lane 1) and preproinsulin fusion protein (lane 2) were separated under denaturing and reducing conditions by 
10% polyacrylamide-SDS gel eleetrophoresis and blotted onto nitrocellulose filter. The separated proteins were stained with 
Coomassie brilliant blue (A) or analyzed by immunoblotting with sera from IDDM patients (B-G) and blood onors (H) which 
were positively assayed for IAA in an ELISA procedure as shown in Fig. 6. As a control the recombinant proteins were visualized 
by immunoblotting using a negative serum from blood donors (I) and an anti-porcine insulin serum from a guinea pig (J). 
genic epitopes within the preproinsulin. One 
serum from the blood donors contained antibod- 
ies directed against recombinant GST. Therefore, 
some reactivity of the recombinant preproinsulin 
fusion protein may also be mediated non-specifi- 
cally by the GST moiety (Fig. 7H). A negative 
serum from blood donors (Fig. 71) and anti- 
porcine insulin serum (Fig. 7J) were included as 
negative and positive controls, respectively. 
Discussion 
The use of modern recombinant technology 
permits the synthesis and purification of human 
proteins in heterologous cell systems which are 
potenially useful for basic research or for many 
medical applications such as diagnostic assay sys- 
tems. Many proteins uch as human preproinsulin 
cannot be obtained from their natural sources in 
suitable quantities because of their low abun- 
dance or difficulty of purification by conventional 
methods from human tissue samples, organs or 
cell lines. One solution is the production of re- 
combinant human proteins in heterologous 
prokaryotic ell systems uch as Escherichia coli 
mediated by suitable and powerful expression 
vectors. In the present paper we describe the 
construction of a novel highly efficient prokary- 
otic expression vector as well as its use for the 
cloning, expression and purification of recombi- 
nant human preproinsulin. An additional aim of 
the present study was to investigate the use of 
recombinant human preproinsulin in ELISA 
screening for insulin autoantibodies (IAA). 
In addition to autoantibodies directed against 
islet cell proteins (Bottazzo et al., 1980) and 
glutamic acid decarboxylase (Baekkeskov et al., 
1982, 1990; Kaufman et al., 1992) the IAA are 
useful in the investigation diagnosis of IDDM 
(Palmer et al., 1983; Atkinson et al., 1986; Dean 
et al., 1986; Wilkin, 1990). In newly diagnosed 
IDDM patients the frequency of IAA is about 
40% in children, but only 4% in adults (Karja- 
lainen et al., 1989). The IAA may arise secondary 
to injury of the/3 cells with subsequent release of 
stored precursors of insulin having antigenic po- 
tential. Therefore, the use of preproinsulin repre- 
senting the entire precursor molecule of insulin 
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may be an appropriate technique for the mea- 
surement of IAA in the sera of patients with 
IDDM because it to also permits the detection of 
antibodies directed against he C-peptide or sig- 
nal peptide. 
A cDNA coding for the full-length human 
preproinsulin was isolated from a cDNA library 
derived from a pancreatic carcinoma cell line by 
screening with corresponding synthetic oligonu- 
cleotides based on the published cDNA sequence 
of human insulin (Goedel et al., 1980). For the 
production of recombinant human preproinsulin 
the cDNA was inserted into the newly designed 
prokaryotic vector pGEX-6T which provides 
high-level expression of a fusion protein with a 
histidine hexapeptide and glutathione-S-trans- 
ferase (GST) at its N-terminus under the control 
of the tac promoter (Amman et al., 1983). 
The pGEX-6T was designed with several ob- 
jectives in mind. Firstly, we wished to express the 
human preproinsulin as a high molecular weight 
fusion protein with the carboxyl terminus of the 
GST from Schistosoma j ponicum (Smith et al., 
1988). The GST moiety is able to mediate protec- 
tion of recombinant proteins against he prote- 
olytic defense system of the host (Smith and 
Johnson, 1988) which is particularly common in 
the bacterial expression of small recombinant 
proteins uch as the 12.5 kDa preproinsulin (data 
not shown). As shown in Figs. 3 and 4 the recom- 
binant preproinsulin fusion protein was over-pro- 
duced in the E. coli after induction with 1 mM 
IPTG and was intracellularly stable for up to 24 
h. Secondly, we introduced a recognition se- 
quence for the site-specific enterokinase (Suet 
al., 1992; Hopp et al., 1988) providing the oppor- 
tunity, if necessary to cleave the GST moiety 
from the recombinant protein. This might be 
advantageous in certain situations, although it 
was not essential in the case of the preproinsulin 
used as antigen in the ELISA measurements. 
Thirdly, we fused a histidine hexapeptide to the 
N-terminus of the recombinant preproinsulin fu- 
sion protein to permit single-step urification by 
affinity chromatography using a metal chelating 
Sepharose charged with Ni 2+ ions (Berthold et 
al., 1992). In general, high-level expression often 
leads to the intracellular accumulation of recom- 
binant proteins in the form of insoluble inclusion 
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bodies. The inclusion bodies are only soluble in 
detergents, strong chaotropic reagents such as 
guanidinium hydrochloride, and in urea. These 
agents normally destroy the natural conformation 
of the recombinant proteins, and therefore pre- 
vent purification by conventional chromatography 
based on interactions with biologically active lig- 
ands. The fusion to a histidine hexapeptide per- 
mitted the ready purification of recombinant pre- 
proinsulin to near homogeneity after solubilizing 
the inclusion bodies with guanidinium-hydrochlo- 
ride followed by affinity chromatography based 
on retention on a Ni2+-Sepharose column and 
elution by a pH step gradient. Subsequent sulfi- 
tolysis (Patrick and Lagu, 1992) is suitable for the 
purification of recombinant proteins with either 
low solubility or high hydrophobicity by prevent- 
ing precipitation after dialysis. Fourthly, we eval- 
uated the most efficient host/vector system for 
pGEX-6T. The recombinant human preproin- 
sulin fusion protein was preferentially produced 
at high levels in the E. coli strains CAG440 and 
CAG456 (Snyder et al., 1987). Because the 
pGEX-6T carries the gene coding for the E. coli 
lac repressor egulation of the expression of re- 
combinant protein is independent on lac repres- 
sor synthesis by the host. 
In order to examine the autoantigenic property 
of the bacterially expressed preproinsulin we 
analysed 43 selected sera from patients with re- 
cently diagnosed IDDM aged between 18 and 30 
years. All sera were positively assayed for autoan- 
tibodies directed against GAD65 (Seissler et al., 
1992). Such autoantibodies are commonly be- 
lieved to be one of the major predictive serum 
markers for IDDM (Baekkeskov et al., 1982, 1990; 
Kaufman et al., 1992). The ELISA procedure 
identified six patients (14%) with autoantibodies 
able to react strongly with recombinant preproin- 
sulin fusion protein. The frequency of IAA in 
sera from IDDM patients measured with the 
recombinant ELISA correlated with previously 
described results (Karjalainen et al., 1989; Wilkin, 
1990; Greenbaum et al., 1992). Only five of the 
IAA positive sera (11.6%) maintained their reac- 
tion with recombinant preproinsulin in im- 
munoblotting analysis confirmes the existence of 
linear antigenic epitopes within the preproin- 
sulin. Bacterially expressed proteins normally lack 
any secondary structure or post-translational 
modifications. Interestingly, comparable studies 
of the same pool of IDDM sera were uniformly 
negative when recombinant mature human in- 
sulin was used as the antigen (data not shown). 
In conclusion, the pGEX-6T construct repre- 
sents a suitable cloning vector for high-level pro- 
duction of recombinant proteins as illustrated 
here for human preproinsulin. The comparable 
measurements of IAA with either recombinant 
preproinsulin or mature insulin suggest that IAA 
in IDDM sera assayed by this recombinant ELISA 
in IDDM could be directed against C-peptide 
or/and signal peptide. Future investigations 
should focus on the mapping of autoantigenic 
epitope(s) within human preproinsulin with a view 
to verifying the autoantigenicity of the C-peptide 
or signal peptide and the generation of IAA in 
the pathogenesis of IDDM. 
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